Spain – Pharmaceutical products – Suministro de Apalutamida(DOE), Paliperidona(DOE),Etravirina(DOE),Daratumumab(DOE),Ibrutinib(DOE),Guselkumab(DOE),Asociación Darunavir/Cobicistat(DOE),Selexipag(DOE),Lazertinib(DOE) Y Amivantamab(DOE)
Suministro de Apalutamida(DOE), Paliperidona(DOE),Etravirina(DOE),Daratumumab(DOE),Ibrutinib(DOE),Guselkumab(DOE),Asociación Darunavir/Cobicistat(DOE),Selexipag(DOE),Lazertinib(DOE) Y Amivantamab(DOE) L1_APALUTAMIDA (DOE) L2_PALIPERIDONA (D
Opportunity description
Suministro de Apalutamida(DOE), Paliperidona(DOE),Etravirina(DOE),Daratumumab(DOE),Ibrutinib(DOE),Guselkumab(DOE),Asociación Darunavir/Cobicistat(DOE),Selexipag(DOE),Lazertinib(DOE) Y Amivantamab(DOE) L1_APALUTAMIDA (DOE) L2_PALIPERIDONA (DOE) L3_ETRAVIRINA (DOE) L4_DARATUMUMAB (DOE) L5_IBRUTINIB (DOE) L6_GUSELKUMAB (DOE) L7_ASOCIACIÓN DARUNAVIR/COBICISTAT (DOE) L8_SELEXIPAG (DOE) L9_LAZERTINIB (DOE) L10_AMIVANTAMAB (DOE) Procedure: neg-wo-call. Estimated value: 201,508,320.72 EUR. Review the original TED notice for the complete requirement, lots, amendments and attachments.
Business details are available after sign in
Codes, capabilities, evidence, buyer details and marketplace actions are withheld from the public HTML and API response.